Genome Editing Market Forecasted to Hit $24.0 Billion by 2030

Posted on 2024-04-05 by MarketDigits in Healthcare // 0 Comments

Richmond, United States, 2024-Apr-05 — /EPR Network/ —

The Genome Editing Market, assessed at USD 6.4 Billion in 2023, is projected to reach USD 24.0 Billion by 2030. This represents a notable compound annual growth rate (CAGR) of 18.0% during the forecast period from 2023 to 2030.

Genome editing, a revolutionary technology that allows precise modifications to DNA, holds immense promise for addressing genetic diseases, advancing agricultural biotechnology, and driving scientific research. The Genome Editing Market encompasses a range of tools, techniques, and applications aimed at modifying genetic material with unprecedented precision and efficiency. In this blog, we’ll delve into the dynamics, significance, key players, and future prospects of the Genome Editing Market.

Request free Sample :
https://www.marketdigits.com/request/sample/3705

Major vendors in the global Genome Editing market:

AstraZeneca
Caribou Biosciences, Inc.
Cellectis S.A.
Cibus
Recombinetics, Inc.
CRISPR Therapeutics
Editas Medicine
Egenesis Inc.
GenScript
Horizon Discovery Group plc
Integrated DNA Technologies, Inc.
Intellia Therapeutics, Inc.
Lonza
Merck KGaA
New England Biolabs
OriGene Technologies, Inc.
Precision Biosciences
Sangamo
Takara Bio USA
Thermo Fisher Scientific, Inc.
Others

Understanding Genome Editing

Genome editing refers to the precise modification of an organism’s DNA using molecular tools, such as CRISPR-Cas9, zinc finger nucleases (ZFNs), and transcription activator-like effector nucleases (TALENs). These technologies enable researchers to make targeted changes to specific genes, including gene knockout, gene insertion, and gene correction, with unprecedented accuracy and efficiency. Genome editing holds promise for a wide range of applications, including gene therapy, drug discovery, agricultural biotechnology, and basic research.

Significance of Genome Editing

The significance of genome editing lies in its ability to:

Treat Genetic Diseases: Genome editing holds promise for the treatment of genetic diseases, such as cystic fibrosis, sickle cell anemia, and muscular dystrophy, by correcting disease-causing mutations at the DNA level, potentially offering cures for previously incurable conditions.
Advance Agricultural Biotechnology: Genome editing techniques enable the precise modification of crop genomes to enhance traits such as yield, disease resistance, and nutritional content, leading to the development of improved crop varieties with enhanced productivity and sustainability.
Accelerate Drug Discovery: Genome editing tools facilitate the study of gene function and disease mechanisms, enabling researchers to identify potential drug targets, validate therapeutic candidates, and develop novel treatments for a wide range of diseases, including cancer, cardiovascular disorders, and neurological conditions.
Drive Basic Research: Genome editing technologies empower researchers to study gene function, genetic regulation, and disease mechanisms with unprecedented precision, advancing our understanding of biology and paving the way for scientific breakthroughs in various fields.

Request for Discount :
https://www.marketdigits.com/request/discount/3705

Market Dynamics and Growth Drivers

The Genome Editing Market is driven by several key factors:

Technological Advancements: Ongoing advancements in genome editing technologies, such as CRISPR-Cas9 and base editing, drive innovation and expand the capabilities of genome editing, enabling more precise, efficient, and versatile DNA modifications.
Rising Demand for Gene Therapy: The growing prevalence of genetic diseases and the increasing adoption of gene therapy as a treatment modality drive demand for genome editing tools and services for the development of gene-based therapies and personalized medicine.
Expansion of Biopharmaceutical R&D: The biopharmaceutical industry’s focus on precision medicine, targeted therapeutics, and genomic profiling fuels demand for genome editing technologies to support drug discovery, preclinical research, and therapeutic development programs.
Investments in Agricultural Biotechnology: The global demand for food security, sustainable agriculture, and climate resilience drives investments in agricultural biotechnology, including genome editing, to develop crop varieties with improved traits and productivity to meet future challenges.

Several companies are prominent players in the Genome Editing Market, including:

CRISPR Therapeutics: CRISPR Therapeutics is a leading biotechnology company focused on the development of CRISPR-based gene therapies for the treatment of genetic diseases, cancer, and immune disorders.
Editas Medicine: Editas Medicine is a clinical-stage biopharmaceutical company specializing in genome editing technologies, including CRISPR-Cas9, for the treatment of genetic disorders and ocular diseases.
Intellia Therapeutics: Intellia Therapeutics is a biotechnology company pioneering the development of CRISPR-based therapies for a range of genetic diseases, including transthyretin amyloidosis and sickle cell disease.
Syngenta: Syngenta is a global agriculture company that leverages genome editing technologies to develop crop traits for improved yield, disease resistance, and environmental sustainability, contributing to global food security and agricultural innovation.

Segmentations Analysis of Genome Editing Market: –

By Technology
- Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9
- Transcription Activator-Like Effector Nuclease (TALENs)/MegaTALs
- Zinc Finger Nuclease (ZFN)
- Meganucleases
- Others
By Method
- Ex-vivo
- In-vivo
By Application
- Genetic Engineering
  - Cell line engineering
  - Animal genetic engineering
  - Plant genetic engineering
  - Others
- Clinical Applications
  - Diagnostics
  - Therapy Development
- Others
End-use
- Biotechnology & pharmaceutical companies
- Academic & government research institutes
- Contract research organizations (CROs)
- Others
By Region
- North America
  - US
  - Canada
- Latin America
  - Brazil
  - Mexico
  - Argentina
  - Colombia
  - Chile
  - Peru
  - Rest of Latin America
- Europe
  - Germany
  - France
  - Italy
  - Spain
  - U.K.
  - BENELUX
  - CIS & Russia
  - Nordics
  - Austria
  - Poland
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - South Korea
  - India
  - Thailand
  - Indonesia
  - Malaysia
  - Vietnam
  - Australia & New Zealand
  - Rest of Asia Pacific
- Middle East & Africa
  - Saudi Arabia
  - UAE
  - South Africa
  - Nigeria
  - Egypt
  - Israel
  - Turkey
  - Rest of MEA

Recent Developments

In October 2023, Intellia Therapeutics announced positive results from a Phase I/II clinical trial of its CRISPR-Cas9 gene editing therapy for sickle cell disease. The therapy was found to be safe and well-tolerated, and it led to significant increases in hemoglobin levels and reductions in the number of sickle cell crises.
In September 2023, Crispr Therapeutics and Vertex Pharmaceuticals announced positive results from a Phase I/II clinical trial of their CRISPR-Cas9 gene editing therapy for beta-thalassemia, a blood disorder. The therapy was found to be safe and well-tolerated, and it led to significant increases in hemoglobin levels in some patients.

Buy Now :
https://www.marketdigits.com/checkout/3705?lic=s

Conclusion:

The Genome Editing Market represents a transformative force in healthcare, agriculture, and biotechnology, offering unprecedented opportunities to address genetic diseases, enhance crop productivity, and drive scientific innovation. With continued advancements in technology, regulatory frameworks, and collaborative research efforts, genome editing has the potential to revolutionize medicine, agriculture, and the life sciences, shaping the future of genetics and genomics in the 21st century.

Matched content

Editor’s pick